16:24 EST Rhythm lowers FY24 non-GAAP opex view to $245M-$255M from $250M-$270M
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- RYTM Upcoming Earnings Report: What to Expect?
- 3 Best Stocks to Buy Now, 10/30/2024, According to Top Analysts
- Rhythm Pharmaceuticals and Axovia Therapeutics sign BBS research collaboration
- Rhythm Pharmaceuticals price target raised to $52 from $48 at BofA
- Biotech Alert: Searches spiking for these stocks today